WORLD ANTI-DOPING CODE

INTERNATIONAL
STANDARD

PROHIBITED LISTJANUARY 2016

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French.
In the event of any conflict between the English and French versions, the English version shall prevail.

IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL
BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.a, AND
PROHIBITED METHODS M1, M2 AND M3.

SUBSTANCES & METHODSPROHIBITED AT ALL TIMES(IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES
Gestrinone;
Mestanolone;
Mesterolone;
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien3-one);
Metenolone;
Methandriol;
Methasterone (17β-hydroxy-2α,17α-dimethyl-5αandrostan-3-one);
Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien3-one);
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5αandrost-1-en-3-one);
Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en3-one);
Methyltestosterone;
Metribolone (methyltrienolone, 17β-hydroxy-17αmethylestra-4,9,11-trien-3-one);
Mibolerone;
Nandrolone;
Norboletone;
Norclostebol;
Norethandrolone;
Oxabolone;
Oxandrolone;
Oxymesterone;
Oxymetholone;
Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'Hpyrazolo[3,4:2,3]-5α-androstane);
Quinbolone;
Stanozolol;
Stenbolone;
Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor17α-pregna-4,9,11-trien-3-one);
Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);

NON-APPROVED SUBSTANCES

S0 Any pharmacological substance which is notaddressed by any of the subsequent sections of the List
and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs
under pre-clinical or clinical development or discontinued,designer drugs, substances approved only for veterinaryuse) is prohibited at all times.

ANABOLIC AGENTS

S1 Anabolic agents are prohibited.
1. ANABOLIC ANDROGENIC STEROIDS (AAS)
a. Exogenous* AAS, including:
1-Androstenediol (5α-androst-1-ene-3β,17β-diol);
1-Androstenedione (5α-androst-1-ene-3,17-dione);
1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one);
4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one);
19-Norandrostenedione (estr-4-ene-3,17-dione);
Bolandiol (estr-4-ene-3β,17β-diol );Bolasterone;
Boldenone;
Boldione (androsta-1,4-diene-3,17-dione);
Calusterone;
Clostebol;
Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy17α-methylandrosta-1,4-dien-3-one);
Desoxymethyltestosterone (17α-methyl-5αandrost-2-en-17β-ol);
Drostanolone;
Ethylestrenol (19-norpregna-4-en-17α-ol);Fluoxymesterone;
Formebolone;
Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5αandrostan-17β-ol);

and other substances with a similar chemical structure
or similar biological effect(s).

2b. Endogenous** AAS when administered exogenously:

2. OTHER ANABOLIC AGENTS

Androstenediol (androst-5-ene-3β,17β-diol);
Androstenedione (androst-4-ene-3,17-dione);
Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one);
Prasterone (dehydroepiandrosterone, DHEA,3β-hydroxyandrost-5-en-17-one);
Testosterone;

Including, but not limited to:
Clenbuterol, selective androgen receptor modulators(SARMs, e.g. andarine and ostarine), tibolone, zeranol
and zilpaterol.
For purposes of this section:* “exogenous” refers to a substance which is not ordinarily
produced by the body naturally.
** “endogenous” refers to a substance which is ordinarily
produced by the body naturally.

and their metabolites and isomers, including but
not limited to:3β-Hydroxy-5α-androstan-17-one;
5α-Androstane-3α,17α-diol;
5α-Androstane-3α,17β-diol;
5α-Androstane-3β,17α-diol;
5α-Androstane-3β,17β-diol;
5β-Androstane-3α,17β-diol;
7α-Hydroxy-DHEA;
7β-Hydroxy-DHEA;
4-Androstenediol (androst-4-ene-3β, 17β-diol)
5-Androstenedione (androst-5-ene-3,17-dione);
7-Keto-DHEA;
19-Norandrosterone;
19-Noretiocholanolone.
Androst-4-ene-3α,17α-diol;
Androst-4-ene-3α,17β-diol;
Androst-4-ene-3β,17α-diol;
Androst-5-ene-3α,17α-diol;
Androst-5-ene-3α,17β-diol;
Androst-5-ene-3β,17α-diol;
Androsterone
Epi-dihydrotestosterone;
Epitestosterone;
Etiocholanolone.

S2 PEPTIDE HORMONES, GROWTH FACTORS,RELATED SUBSTANCES AND MIMETICSThe following substances, and other substances withsimilar chemical structure or similar biological effect(s),are prohibited:
1. Erythropoietin-Receptor agonists:
1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g.
Darbepoietin (dEPO);
Erythropoietins (EPO);
EPO-Fc;EPO-mimetic peptides (EMP), e.g. CNTO 530 andpeginesatide; methoxy polyethylene glycol-epoetinbeta (CERA).
1.2 Non-erythropoietic EPO-Receptor agonists, e.g.
ARA-290;
asialo EPO;
carbamylated EPO.
2.	Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt
and FG-4592; and HIF activators, e.g. argon, xenon;
3.	Chorionic Gonadotrophin (CG) and Luteinizing
Hormone (LH) and their releasing factors, e.g. buserelin,
gonadorelin and leuprorelin, in males;
4.	Corticotrophins and their releasing factors,e.g corticorelin;

3

S4 HORMONE AND METABOLIC

5.	Growth Hormone (GH) and its releasing factors including:Growth Hormone Releasing Hormone (GHRH) and its
analogues, e.g. CJC-1295, sermorelin and tesamorelin;
Growth Hormone Secretagogues (GHS), e.g. ghrelinand ghrelin mimetics, e.g. anamorelin and ipamorelin;
GH-Releasing Peptides (GHRPs), e.g. alexamorelin,
GHRP-6, hexarelin and pralmorelin (GHRP-2).

MODULATORSThe following hormone and metabolic modulators
are prohibited:
1.	Aromatase inhibitors including, but not limited to:4-Androstene-3,6,17 trione (6-oxo);
Aminoglutethimide;
Anastrozole;
Androsta-1,4,6-triene-3,17-dione (androstatrienedione);
Exemestane;
Formestane;
Letrozole;
Testolactone.

Additional prohibited growth factors:
Fibroblast Growth Factors (FGFs);
Hepatocyte Growth Factor (HGF);
Insulin-like Growth Factor-1 (IGF-1) and its analogues;
Mechano Growth Factors (MGFs);
Platelet-Derived Growth Factor (PDGF);
Vascular-Endothelial Growth Factor (VEGF)

2.	Selective estrogen receptor modulators (SERMs)
including, but not limited to:
Raloxifene;
Tamoxifen;
Toremifene.

and any other growth factor affecting muscle, tendon orligament protein synthesis/degradation, vascularisation,energy utilization, regenerative capacity or fibre typeswitching.

3.	Other anti-estrogenic substances including, but notlimited to:
Clomiphene;
Cyclofenil;
Fulvestrant.

BETA-2 AGONISTS

S3 All beta-2 agonists, including all optical isomers,e.g. d- and l- where relevant, are prohibited.
Except:• Inhaled salbutamol (maximum 1600 micrograms over24 hours);• Inhaled formoterol (maximum delivered dose
54 micrograms over 24 hours); and• Inhaled salmeterol in accordance with themanufacturers’ recommended therapeutic regimen.

4.	Agents modifying myostatin function(s) including, but
not limited, to: myostatin inhibitors.
5. Metabolic modulators:
5.1 Activators of the AMP-activated protein kinase(AMPK), e.g. AICAR; andPeroxisome Proliferator Activated Receptor δ 		(PPARδ) agonists, e.g. GW 1516;
5.2 Insulins and insulin-mimetics;
5.3 Meldonium;
5.4 Trimetazidine.

The presence in urine of salbutamol in excess of1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of thesubstance and will be considered as an Adverse Analytical
Finding (AAF ) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result
was the consequence of the use of the therapeutic inhaled
dose up to the maximum indicated above.

4PROHIBITED METHODSS5 DIURETICS AND MASKING AGENTS

M1 MANIPULATION OF BLOOD AND
BLOOD COMPONENTS

The following diuretics and masking agents areprohibited, as are other substances with a similar chemical
structure or similar biological effect(s).

The following are prohibited:
1.	The Administration or reintroduction of any quantity ofautologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into thecirculatory system.

Including, but not limited to:• Desmopressin; probenecid; plasma expanders, e.g.
glycerol and intravenous administration of albumin,
dextran, hydroxyethyl starch and mannitol.
• Acetazolamide; amiloride; bumetanide; canrenone;
chlortalidone; etacrynic acid; furosemide; indapamide;
metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide;
triamterene and vaptans, e.g. tolvaptan.

2.	Artificially enhancing the uptake, transport or deliveryof oxygen. Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13) and modified
haemoglobin products, e.g. haemoglobin-based blood
substitutes and microencapsulated haemoglobin
products, excluding supplemental oxygen.
3.	Any form of intravascular manipulation of the bloodor blood components by physical or chemical means.

Except:• Drospirenone; pamabrom; and ophthalmic use ofcarbonic anhydrase inhibitors (e.g. dorzolamide,brinzolamide).
• Local administration of felypressin in dental
anaesthesia.

M2 CHEMICAL AND PHYSICALMANIPULATION

The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter theintegrity and validity of Samples collected during
Doping Control.
Including, but not limited to:Urine substitution and/or adulteration, e.g. proteases.

The detection in an Athlete’s Sample at all times orIn-Competition, as applicable, of any quantity of thefollowing substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine
and pseudoephedrine, in conjunction with a diuretic ormasking agent, will be considered as an Adverse Analytical
Finding unless the Athlete has an approved TUE for that
substance in addition to the one granted for the diureticor masking agent.

2. Intravenous infusions and/or injections of more than50 mL per 6 hour period except for those legitimately
received in the course of hospital admissions, surgicalprocedures or clinical investigations.

M3GENE DOPING

The following, with the potential to enhance sport
performance, are prohibited:
1. The transfer of polymers of nucleic acids or nucleic
acid analogues;
2.	The use of normal or genetically modified cells.

5SUBSTANCES & METHODSPROHIBITED IN-COMPETITIONIN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIESARE PROHIBITED IN-COMPETITION:

PROHIBITED SUBSTANCESSTIMULANTS

b: Specified Stimulants.
Including, but not limited to:

S6 All stimulants, including all optical isomers, e.g.
d- and l- where relevant, are prohibited.

Benzfetamine;
Cathine**;Cathinone and its analogues, e.g. mephedrone,
methedrone, and α- pyrrolidinovalerophenone;
Dimethylamphetamine;
Ephedrine***;Epinephrine**** (adrenaline);
Etamivan;Etilamfetamine;
Etilefrine;
Famprofazone;
Fenbutrazate;
Fencamfamin;
Heptaminol;
Hydroxyamfetamine (parahydroxyamphetamine);
Isometheptene;
Levmetamfetamine;
Meclofenoxate;
Methylenedioxymethamphetamine;
Methylephedrine***;Methylhexaneamine (dimethylpentylamine);
Methylphenidate;
Nikethamide;
Norfenefrine;
Octopamine;
Oxilofrine (methylsynephrine);
Pemoline;
Pentetrazol;
Phenethylamine and its derivatives;
Phenmetrazine;
Phenpromethamine;
Propylhexedrine;
Pseudoephedrine*****;
Selegiline;

Stimulants include:
a: Non-Specified Stimulants:
Adrafinil;
Amfepramone;
Amfetamine;
Amfetaminil;
Amiphenazole;
Benfluorex;
Benzylpiperazine;
Bromantan;
Clobenzorex;
Cocaine;Cropropamide;
Crotetamide;
Fencamine;
Fenetylline;
Fenfluramine;
Fenproporex;
Fonturacetam [4-phenylpiracetam (carphedon)];Furfenorex;
Mefenorex;
Mephentermine;
Mesocarb;
Metamfetamine(d-);
p-Methylamphetamine;
Modafinil;
Norfenfluramine;
Phendimetrazine;
Phentermine;
Prenylamine;
Prolintane.
A stimulant not expressly listed in this section
is a Specified Substance.
6

Sibutramine;
Strychnine;
Tenamfetamine (methylenedioxyamphetamine);
Tuaminoheptane;

S7

NARCOTICS

Prohibited:
Buprenorphine;
Dextromoramide;
Diamorphine (heroin);
Fentanyl and its derivatives;
Hydromorphone;
Methadone;
Morphine;
Oxycodone;
Oxymorphone;
Pentazocine;Pethidine.

and other substances with a similar chemical structure
or similar biological effect(s).
Except:• Clonidine• Imidazole derivatives for topical/ophthalmic use andthose stimulants included in the 2016 Monitoring
Program*.
* 	Bupropion, caffeine, nicotine, phenylephrine,phenylpropanolamine, pipradrol, and synephrine: These
substances are included in the 2016 Monitoring Program, andare not considered Prohibited Substances.
** 	Cathine: Prohibited when its concentration in urine is greaterthan 5 micrograms per milliliter.
*** 	Ephedrine and methylephedrine: Prohibited when theconcentration of either in urine is greater than 10 micrograms
per milliliter.
****	Epinephrine (adrenaline): Not prohibited in local administration,e.g. nasal, ophthalmologic, or co-administration with local
anaesthetic agents.
***** 	Pseudoephedrine: Prohibited when its concentration in urine
is greater than 150 micrograms per milliliter.

S8CANNABINOIDS

Prohibited:• Natural, e.g. cannabis, hashish and marijuana, orsynthetic Δ9-tetrahydrocannabinol (THC).
• Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073,HU-210.

GLUCOCORTICOIDS

S9 All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

7

SUBSTANCES PROHIBITED
IN PARTICULAR SPORTS

ALCOHOL

BETA-BLOCKERS

P1 Alcohol (ethanol) is prohibited In-Competition only,

P2 Beta-blockers are prohibited In-Competitionin the following sports. Detection will be conducted byanalysis of breath and/or blood. The doping violationthreshold is equivalent to a blood alcohol concentrationof 0.10 g/L.

only, in the following sports, and also prohibited
Out-of-Competition where indicated.

• Air Sports (FAI)• Automobile (FIA)• Automobile (FIA)• Archery (WA)• Powerboating (UIM)• Billiards (all disciplines) (WCBS)• Archery (WA)*• Darts (WDF)• Golf (IGF)• Shooting (ISSF, IPC)*• Skiing/Snowboarding (FIS) in ski jumping, freestyleaerials/halfpipe and snowboard halfpipe/big air• Underwater sports (CMAS) in constant-weight apnoea
with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea,
spearfishing, static apnoea, target shooting and variableweight apnoea.
*Also prohibited Out-of-Competition

Including, but not limited to:
Acebutolol;
Alprenolol;
Atenolol;
Betaxolol;
Bisoprolol;
Bunolol;
Carteolol;
Carvedilol;
Celiprolol;
Esmolol;

8Labetalol;
Levobunolol;
Metipranolol;
Metoprolol;
Nadolol;
Oxprenolol;
Pindolol;
Propranolol;
Sotalol;
Timolol.

www.wada-ama.org